<h2>Mirum Pharmaceuticals：近期表現快照</h2>
<p>Mirum Pharmaceuticals (MIRM) 在今年表現強勁，吸引了關注，股價上漲約 31%，過去一年總回報約為 127%。</p>
<p>查看我們對 Mirum Pharmaceuticals 的最新分析。</p>
<p>在這段強勁的表現後，股價最近有所回落，最新收盤價為 102.19 美元，1 天股價回報下跌 8.3%，7 天股價回報下跌 4.6%。1 年總股東回報仍然非常可觀，5 年總股東回報接近 5 倍。</p>
<p>如果你對罕見疾病的投資感興趣，可以通過掃描 32 只醫療保健 AI 股票，瞭解其他相關動態。</p>
<p>目前 Mirum Pharmaceuticals 的估值約為 68 億美元，且交易價格低於一些分析師的目標和內在估計，你不得不問：這是一隻打折的罕見疾病股票，還是市場已經在定價未來的增長？</p>
<h2>最受歡迎的敍述：低估 21.2%</h2>
<p>在最新收盤價 102.19 美元與最受關注的公允價值估計約 129.73 美元相比，目前 Mirum Pharmaceuticals 的價格遠低於這一敍述目標，該目標基於對未來收入增長、盈利能力和現金流的詳細假設，折現率為 7.24%。</p>
<blockquote>
<p><em>多個晚期管線催化劑，包括未來 24 個月內的三項關鍵研究結果（VISTAS、VANTAGE、EXPAND）以及 II 期脆性 X 研究的啓動，為進一步的產品標籤擴展和新適應症推出奠定了基礎，支撐未來收入多樣化和潛在盈利加速。</em></p>
</blockquote>
<p>閲讀完整敍述。</p>
<p>想知道為了維持這種估值需要什麼樣的收入曲線和利潤率嗎？這個敍述依賴於持續的兩位數頂線擴張，從當前虧損到正盈利的明確路徑，以及與更快增長行業更常見的前瞻性利潤倍數。想看看這些動態如何結合在一起，以及市場將為這些未來盈利支付多少？</p>
<p><strong>結果：公允價值 129.73 美元（低估）</strong></p>
<p>完整閲讀敍述，瞭解預測背後的原因。</p>
<p>然而，如果關鍵註冊試驗未能如預期，或罕見疾病定價壓力限制 Livmarli 和膽汁酸組合的收入潛力，這一敍述可能會迅速轉變。</p>
<p>瞭解 Mirum Pharmaceuticals 敍述的關鍵風險。</p>
<h2>另一種看待估值的方法</h2>
<p>早期的公允價值觀點在很大程度上依賴於詳細的現金流和盈利預測。一個更簡單的檢查是使用當前的市銷率 10.9 倍，與美國生物科技行業的 10.9 倍、同行的 11.5 倍和公允比率的 9.3 倍相比，這表明價格標籤更高，若增長或定價假設放緩，容錯空間較小。</p>
<p>查看數字對這一價格的看法——在我們的估值分析中瞭解更多。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f966f0bc-3bcf-474b-a9d5-fe32e1bb6c62/chart/ps-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTE2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1640" height="650" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f966f0bc-3bcf-474b-a9d5-fe32e1bb6c62/chart/ps-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTE2"/></p>
<p>NasdaqGM:MIRM 截至 2026 年 5 月的市銷率</p>
<h2>下一步</h2>
<p>看到文章中既有強勁回報又有估值爭論，檢查基礎數據、權衡潛在收益和風險，然後決定你對當前設置的舒適度，回顧 3 個關鍵收益和 2 個重要警示信號是明智的。</p>
<h2>尋找更多投資想法？</h2>
<p>不要止步於單一股票故事。通過篩選器擴展你的觀察名單，獲取關注質量、價值和韌性的股票想法。</p>
<ul>
<li>通過掃描 50 只高質量低估股票，尋找潛在的錯誤定價，這些股票結合了穩健的基本面和未完全反映其財務狀況的價格。</li>
<li>通過審查 12 只高股息股票，增強你的收入流，這些股票強調了持久性。</li>
<li>通過檢查 66 只低風險股票，減少投資組合的意外，這些公司具有更強的財務和風險韌性。</li>
</ul>
<p><em>本文由 Simply Wall St 撰寫，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，僅使用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮你的目標或財務狀況。我們旨在為你提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<h3><strong>新功能：在一個地方管理所有股票投資組合</strong></h3>
<p>我們為股票投資者創建了 <strong>終極投資組合助手</strong>，<strong>並且是免費的。</strong></p>
<p>• 連接無限數量的投資組合，並以一種貨幣查看你的總額</p>
<p>• 通過電子郵件或手機接收新的警示信號或風險提示</p>
<p>• 跟蹤你股票的公允價值</p>
<p>免費試用演示投資組合</p>

MIRM

<p>Mirum Pharmaceuticals (MIRM) 今年表現強勁，股價上漲了 31%，但最近出現回調，收盤價為 102.19 美元，單日下跌 8.3%。分析師估計其公允價值為 129.73 美元，暗示該股票被低估。公司有多個晚期管線催化劑可能推動未來增長，但如果關鍵試驗失利或面臨價格壓力，仍然存在風險</p>

<h2>Mirum Pharmaceuticals: recent performance snapshot</h2>
<div class="lb-trans"><h2>Mirum Pharmaceuticals：近期表現快照</h2>
</div><p>Mirum Pharmaceuticals (MIRM) has attracted attention after a strong year to date, with the stock up about 31% and a total return of roughly 127% over the past year.</p>
<div class="lb-trans"><p>Mirum Pharmaceuticals (MIRM) 在今年表現強勁，吸引了關注，股價上漲約 31%，過去一年總回報約為 127%。</p>
</div><p>See our latest analysis for Mirum Pharmaceuticals.</p>
<div class="lb-trans"><p>查看我們對 Mirum Pharmaceuticals 的最新分析。</p>
</div><p>After this strong run, the share price has recently cooled, with the latest close at $102.19, a 1 day share price return of down 8.3% and a 7 day share price return of down 4.6%. The 1 year total shareholder return remains very large and the 5 year total shareholder return sits near 5x.</p>
<div class="lb-trans"><p>在這段強勁的表現後，股價最近有所回落，最新收盤價為 102.19 美元，1 天股價回報下跌 8.3%，7 天股價回報下跌 4.6%。1 年總股東回報仍然非常可觀，5 年總股東回報接近 5 倍。</p>
</div><p>If rare disease exposure has your attention, it can be useful to see what else is moving in healthcare by scanning 32 healthcare AI stocks</p>
<div class="lb-trans"><p>如果你對罕見疾病的投資感興趣，可以通過掃描 32 只醫療保健 AI 股票，瞭解其他相關動態。</p>
</div><p>With Mirum Pharmaceuticals now valued at about US$6.8b and trading at a discount to some analyst targets and intrinsic estimates, you have to ask: is this a rare disease stock on sale, or is the market already pricing in future growth?</p>
<div class="lb-trans"><p>目前 Mirum Pharmaceuticals 的估值約為 68 億美元，且交易價格低於一些分析師的目標和內在估計，你不得不問：這是一隻打折的罕見疾病股票，還是市場已經在定價未來的增長？</p>
</div><h2>Most Popular Narrative: 21.2% Undervalued</h2>
<div class="lb-trans"><h2>最受歡迎的敍述：低估 21.2%</h2>
</div><p>At a last close of $102.19 versus a most followed fair value estimate of about $129.73, the current Mirum Pharmaceuticals price sits well below that narrative target, which is built on detailed assumptions about future revenue growth, profitability and cash flows discounted at 7.24%.</p>
<div class="lb-trans"><p>在最新收盤價 102.19 美元與最受關注的公允價值估計約 129.73 美元相比，目前 Mirum Pharmaceuticals 的價格遠低於這一敍述目標，該目標基於對未來收入增長、盈利能力和現金流的詳細假設，折現率為 7.24%。</p>
</div><blockquote>
<p><em>Multiple late-stage pipeline catalysts, including three pivotal study readouts (VISTAS, VANTAGE, EXPAND) over the next 24 months and the initiation of the Phase II Fragile X study, set the stage for further product label expansions and new indication launches, underpinning future revenue diversification and potential earnings acceleration.</em></p>
</blockquote>
<div class="lb-trans"><blockquote>
<p><em>多個晚期管線催化劑，包括未來 24 個月內的三項關鍵研究結果（VISTAS、VANTAGE、EXPAND）以及 II 期脆性 X 研究的啓動，為進一步的產品標籤擴展和新適應症推出奠定了基礎，支撐未來收入多樣化和潛在盈利加速。</em></p>
</blockquote>
</div><p>Read the complete narrative.</p>
<div class="lb-trans"><p>閲讀完整敍述。</p>
</div><p>Curious what kind of revenue curve and margin profile would need to play out for this valuation to hold up? The narrative leans on sustained double digit top line expansion, a clear path from current losses into positive earnings, and a forward profit multiple more often associated with faster growing sectors. Want to see how those moving parts fit together and what the market would be asked to pay for those future earnings?</p>
<div class="lb-trans"><p>想知道為了維持這種估值需要什麼樣的收入曲線和利潤率嗎？這個敍述依賴於持續的兩位數頂線擴張，從當前虧損到正盈利的明確路徑，以及與更快增長行業更常見的前瞻性利潤倍數。想看看這些動態如何結合在一起，以及市場將為這些未來盈利支付多少？</p>
</div><p><strong>Result: Fair Value of $129.73 (UNDERVALUED)</strong></p>
<div class="lb-trans"><p><strong>結果：公允價值 129.73 美元（低估）</strong></p>
</div><p>Have a read of the narrative in full and understand what's behind the forecasts.</p>
<div class="lb-trans"><p>完整閲讀敍述，瞭解預測背後的原因。</p>
</div><p>However, this narrative can quickly shift if key registrational trials disappoint, or if pressure on rare disease pricing limits Livmarli and bile acid portfolio revenue potential.</p>
<div class="lb-trans"><p>然而，如果關鍵註冊試驗未能如預期，或罕見疾病定價壓力限制 Livmarli 和膽汁酸組合的收入潛力，這一敍述可能會迅速轉變。</p>
</div><p>Find out about the key risks to this Mirum Pharmaceuticals narrative.</p>
<div class="lb-trans"><p>瞭解 Mirum Pharmaceuticals 敍述的關鍵風險。</p>
</div><h2>Another way to look at the valuation</h2>
<div class="lb-trans"><h2>另一種看待估值的方法</h2>
</div><p>The earlier fair value view leans heavily on detailed cash flow and earnings forecasts. A simpler check uses the current P/S of 10.9x compared with the US Biotechs industry at 10.9x, peers at 11.5x and a fair ratio of 9.3x, which points to a richer price tag and less margin for error if growth or pricing assumptions soften.</p>
<div class="lb-trans"><p>早期的公允價值觀點在很大程度上依賴於詳細的現金流和盈利預測。一個更簡單的檢查是使用當前的市銷率 10.9 倍，與美國生物科技行業的 10.9 倍、同行的 11.5 倍和公允比率的 9.3 倍相比，這表明價格標籤更高，若增長或定價假設放緩，容錯空間較小。</p>
</div><p>See what the numbers say about this price — find out in our valuation breakdown.</p>
<div class="lb-trans"><p>查看數字對這一價格的看法——在我們的估值分析中瞭解更多。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f966f0bc-3bcf-474b-a9d5-fe32e1bb6c62/chart/ps-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTE2" alt="" original-src="https://images.simplywall.st/company/f966f0bc-3bcf-474b-a9d5-fe32e1bb6c62/chart/ps-multiple-vs-industry?date=2026-05-16"/></p>
<p>NasdaqGM:MIRM P/S Ratio as at May 2026</p>
<div class="lb-trans"><p>NasdaqGM:MIRM 截至 2026 年 5 月的市銷率</p>
</div><h2>Next Steps</h2>
<div class="lb-trans"><h2>下一步</h2>
</div><p>Seeing both strong returns and valuation debate in the article, it makes sense to check the underlying data, weigh the upside and the risks, and then decide how comfortable you are with the current setup by reviewing the 3 key rewards and 2 important warning signs</p>
<div class="lb-trans"><p>看到文章中既有強勁回報又有估值爭論，檢查基礎數據、權衡潛在收益和風險，然後決定你對當前設置的舒適度，回顧 3 個關鍵收益和 2 個重要警示信號是明智的。</p>
</div><h2>Looking for more investment ideas?</h2>
<div class="lb-trans"><h2>尋找更多投資想法？</h2>
</div><p>Do not stop with a single stock story. Broaden your watchlist with focused stock ideas sourced from screeners that highlight quality, value and resilience.</p>
<div class="lb-trans"><p>不要止步於單一股票故事。通過篩選器擴展你的觀察名單，獲取關注質量、價值和韌性的股票想法。</p>
</div><ul>
<li>Target potential mispricings by scanning 50 high quality undervalued stocks that combine solid fundamentals with prices that do not fully reflect their financial profile.</li>
<li>Strengthen your income stream by reviewing 12 dividend fortresses that pair higher yields with an emphasis on staying power.</li>
<li>Reduce portfolio surprises by checking 66 resilient stocks with low risk scores built around companies with more resilient financial and risk profiles.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過掃描 50 只高質量低估股票，尋找潛在的錯誤定價，這些股票結合了穩健的基本面和未完全反映其財務狀況的價格。</li>
<li>通過審查 12 只高股息股票，增強你的收入流，這些股票強調了持久性。</li>
<li>通過檢查 66 只低風險股票，減少投資組合的意外，這些公司具有更強的財務和風險韌性。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰寫，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，僅使用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮你的目標或財務狀況。我們旨在為你提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：在一個地方管理所有股票投資組合</strong></h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我們為股票投資者創建了 <strong>終極投資組合助手</strong>，<strong>並且是免費的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 連接無限數量的投資組合，並以一種貨幣查看你的總額</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通過電子郵件或手機接收新的警示信號或風險提示</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟蹤你股票的公允價值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免費試用演示投資組合</p>
</div>

在經歷了強勁的一年後，評估 Mirum Pharmaceuticals (MIRM) 的估值及其近期股價回調